Jamie focuses her practice on corporate healthcare transactions, assisting in due diligence, as well as in the review and preparation of contracts, agreements, and closing documents. Jamie counsels clients on a broad range of healthcare-related matters, including the corporate practice of medicine, state laws related to licensure, healthcare fraud and abuse laws such as the Anti-Kickback Statute and the Stark Law, and state and federal regulatory and privacy laws, including compliance with HIPAA’s Privacy, Security, and Breach Notification Rules. In addition, she researches and analyzes healthcare industry and regulatory developments to advise clients on potential risks and opportunities.
*Matter completed prior to joining Benesch.
Representative Experience
- Represented a credit investment firm as health care regulatory counsel related to the purchase of three skilled nursing facilities in Florida.
-
Represented a fertility practice and its associated ambulatory surgical center in their sale to a fertility clinic.
- Represented private equity sponsor in its simultaneous acquisitions of an oncology practice service provider and a group purchasing organization.
- Represented a private equity firm that invests in the industrial, healthcare, and technology services sectors in its purchase of a healthcare staffing agency focused on providing healthcare personnel to federal and commercial hospitals.*
- Represented one of the nation’s largest treatment providers for individuals diagnosed with autism spectrum disorder and its affiliates in their Chapter 11 cases in U.S. Bankruptcy Court.*
- Represented a leading global healthcare services outsourcing company in its sale to a private equity firm.*
- Represented a private equity firm who invests in growth-stage companies in its acquisition of a Medicare Advantage member engagement and navigation platform.*
- Represented a leading software investment firm in a medication intelligence company’s acquisition of a pioneer in drug diversion monitoring.*
- Represented a leading provider of home infusion services in its proposed $3.6 billion merger with a provider of home health, hospice, and high-acuity care.*
- Represented a leading software investment firm, in its acquisition of a medication intelligence company.*